This analysis examines the historical and forecast performance for Solvay in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Solvay's performance against key rivals in the ethical pharmaceutical sector See how the launch of bifeprunox will drive Solvay's growth to 2011, offsetting the decline of many of the company's currently marketed products Evaluate Solvay's progress in integrating Fournier and the prospects of its key dyslipidemia product, fenofibrate